Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice

Journal of Clinical Investigation

Volumn 115, Issue 9, 2005, Pages 2434-2443

  Vikramadithyan, Reeba K ^a   Hu, Yunying ^a   Noh, Hye Lim ^a   Liang, Chien Ping ^a   Hallam, Kellie ^a   Tall, Alan R ^a   Ramasamy, Ravichandran ^a   Goldberg, Ira J ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; CHOLESTEROL; CHOLIC ACID; LOW DENSITY LIPOPROTEIN RECEPTOR; STREPTOZOCIN;

ANIMAL CELL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; GLUCOSE METABOLISM; GLUTATHIONE METABOLISM; HYPERGLYCEMIA; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; STREPTOZOCIN DIABETES; TRANSGENIC MOUSE;

ALDEHYDE REDUCTASE; ANIMALS; AORTA; ATHEROSCLEROSIS; BLOOD GLUCOSE; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; DIET, ATHEROGENIC; HUMANS; LIPIDS; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MYOCARDIUM; RECEPTORS, LDL; RISK FACTORS;

EID: 24644491335     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI24819     Document Type: Article

References (48)

1. Anonymous. 1998. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 352:837-853.
2. Diabetes Control and Complications Trial. 1995. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am. J. Cardiol. 75:894-903.
3. Goldberg, I.J. 2004. Why does diabetes increase atherosclerosis? I don't know! J. Clin. Invest. 114:613-615. doi:10.1172/JCI200422826.
4. Mathe, D. 1995. Dyslipidemia and diabetes: animal models [review]. Diabete Metab. 21:106-111.
5. Keren, P., et al. 2000. Effect of hyperglyeemia and hyperlipidemia on atherosclerosis in LDL receptor-deficient mice: establishment of a combined model and association with heat shock protein 65 immunity. Diabetes. 49:1064-1069.
6. Hasty, A. H., et al. 2001. Severe hypercholesterolemia, hypertriglyceridemia, and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor. J. Biol. Chem. 276:37402-37408.
7. Park, L., et al. 1998. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med. 4:1025-1031.
8. Renard, C.B., et al. 2004. Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J Clin. Invest. 114:659-668. doi:10.1172/JCI200417867.
9. Reaven, P., Merat, S., Casanada, F., Sutphin, M., and Palinski, W. 1997. Effect of streptozotocin-induced hyperglycemia on lipid profiles, formation of advanced glycation endproducts in lesions, and extent of atherosclerosis in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol 17:2250-2256.
10. Kako, Y., et al. 1999. Streptozotocin-induced diabetes in human apolipoprotein B transgenic mice. Effects on lipoproreins and atherosclerosis. J. Lipid Res. 40:2185-2194.
11. Merat, S., Casanada, F., Sutphin, M., Palinski, W., and Reaven, P.D. 1999. Western-type diets induce insulin resistance and hyperinsulinemia in LDL receptor-deficient mice but do not increase aortic atherosclerosis compared with normoinsulinemic mice in which similar plasma cholesterol levels are achieved by a fructose-rich diet. Arterioscler. Thromb. Vasc. Biol. 19:1223-1230.
12. Brownlee, M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature. 414:813-820.
13. Pfeifer, M.A., Schumer, M.P., and Gelber, D.A. 1997. Aldose reductase inhibitors: the end of an era or the need for different trial designs? [review]. Diabetes. 46(Suppl. 2):S82-S89.
14. Martyn, C.N., Reid, W., Young, RJ., Ewing, D.J., and Clarke, B.F. 1987. Six-month treatment with sorbinil in asymptomatic diabetic neuropathy. Failure to improve abnormal nerve function. Diabetes. 36:987-990.
15. Bril, V., and Buchanan, R.A. 2004. Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy. Diabetes Care. 27:2369-2375.
16. Gabbay, K.H. 2004. Aldose reductase inhibition in the treatment of diabetic neuropathy: where are we in 2004? [review]. Curr. Diab. Rep. 4:405-408.
17. Ramasamy, R., Oates, P.J., and Schaefer, S. 1997. Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury. Diabetes. 46:292-300.
18. Johnson, B.F., et al. 2004. Cardiac abnormalities in diabetic patients with neuropathy: effects of aldose reductase inhibitor administration. Diabetes Care. 27:448-454.
19. Hwang, Y.C., et al. 2004. Central role for aldose reductase pathway in myocardial ischemic injury. FASEB J. 18:1192-1199.
20. Markus, H.B., Raducha, M., and Harris, H. 1983. Tissue distribution of mammalian aldose reductase and related enzymes. Biochem. Med. 29:31-45.
21. Tanimoto, T., Maekawa, K., Okada, S., and Yabe-Nishimura, C. 1998. Clinical analysis of aldose reductase for different diagnosis of the pathogenesis of diabetic complication. Anal. Chim. Acta. 365:285-292.
22. Yamaoka, T., et al. 1995. Acute onset of diabetic pathological changes in transgenic mice with human aldose reductase cDNA. Diabetologia. 38:255-261.
23. Hwang, Y.C., et al. 2002. Aldose reductase activation is a key component of myocardial response to ischemia. FASEB J. 16:243-245.
24. Kako, Y., Masse, M., Huang, L.S., Tall, A.R., and Goldberg, I.J. 2002. Lipoprotein lipase deficiency and CETP in streptozotocin-treated apoB-expressing mice. J. Lipid Res. 43:872-877.
25. Arai, T., Wang, N., Bezouevski, M., Welch, C., and Tall, A.R. 1999. Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene. J. Biol. Chem. 274:2366-2371.
26. van Haperen, R., et al. 2002. Increased risk of atherosclerosis by elevated plasma levels of phospholipid Transfer protein. J. Biol. Chem. 277:48938-48943.
27. Khalil, M.F., Wagner, W.D., and Goldberg, I.J. 2004. Molecular interactions leading to lipoprotein retention and the initiation of atherosclerosis [review]. Arterioscler. Thromb. Vasc. Biol 24:2211-2218.
28. Koishi, R., et al. 2002. Angptl3 regulates lipid metabolism in mice. Nat. Genet. 30:151-157.
29. Vergnes, L., Phan,J., Strauss, M., Tafurr, S., and Reue, K. 2003. Cholesterol and cholate components of an atherogenic diet induce distinct stages of hepatic inflammatory gene expression. J. Biol Chem. 278:42774-42784.
30. Waller, B.F., Palumbo, P.J., Lie, J.-T., and Roberts, W.C. 1980. Status of the coronary arteries at necropsy in diabetes mellitus with onset after age 30 years. Analysis of 229 diabetic patients with and without clinical evidence of coronary heart disease and comparison to 183 control subjects. Am. J. Med. 69:498-506.
31. Luoma, J.S., et al. 1998. Expression of extracellular SOD and iNOS in macrophages and smooth muscle cells in human and rabbit atherosclerotic lesions: colocalization with epitopes characteristic of oxidized LDL and peroxynitrite-modified proteins [review]. Arterioscler. Thromb. Vasc. Biol. 18:157-167.
32. Luoma, J.S., and Yla-Herttuala, S. 1999. Expression of inducible nitric oxide synthase in macrophages and smooth muscle cells in various types of human atherosclerotic lesions. Virchows Arch. 434:561-568.
33. Seino, Y., et al. 1994. Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine. 6:87-91.
34. Sukovich, D.A., et al. 1998. Expression of interleukin-6 in atherosclerotic lesions of male ApoE-knockout mice: inhibition by 17beta-estradiol. Arterioscler. Thromb. Vasc. Biol. 18:1498-1505.
35. Schieffer, B., et al. 2004. Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation. 110:3493-3500.
36. Endemann, G., et al. 1993. CD36 is a receptor for oxidized low density lipoprotein. J. Biol. Chem. 268:11811-11816.
37. Linton, M.F., and Fazio, S. 2001. Class A scavenger receptors, macrophages, and atherosclerosis. Curr. Opin. Lipidol. 12:489-495.
38. Fukuhara-Takaki, K., Sakai, M., Sakamoto, Y.I., Takeya, M., and Horiuchi, S. 2004. Expression of class A scavenger receptor is enhanced by high glucose in vitro and under diabetic conditions in vivo: one mechanism for an increased rate of atherosclerosis in diabetes. J. Biol. Chem. 280:3355-3364.
39. Liang, C.P., et al. 2004. Increased CD36 protein as a response to defective insulin signaling in macrophages. J. Clin. Invest. 113:764-773. doi:10.1172/JCI200419528.
40. Vincent, A.M., Russell, J.W., Low, P., and Feldman, B.L. 2004. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr. Rev. 25:612-628.
41. Demaine, A.G. 2003. Polymorphisms of the aldose reductase gene and susceptibility to diabetic microvascular complications, Curr. Med. Chem. 10:1389-1398.
42. Ii, S., et al. 2004. Redox state-dependent and sorbitol accumulation-independent diabetic albuminuria in mice with transgene-derived human aldose reductase and sorbitol dehydrogenase deficiency. Diabetologia. 47:541-548.
43. Nishimura, C., et al. 1990. Cloning and expression of human aldose reductase. J. Biol. Chem. 265:9788-9792.
44. Gaw, A., Mancini, F.P., and Ishibashi, S. 1995. Rapid genotypmg of low density lipoprotein receptor knockout mice using a polymerase chain reaction technique. Lab. Anim. 29:447-449.
45. Teupser, D., Persky, A.D., and Breslow, J.L. 2003. Induction of atherosclerosis by low-far, semisynthetic diets in LDL receptor-deficient C57BL/6J and FVB/NJ mice: comparison of lesions of the aortic root, brachiocephalic artery, and whole aorta (en face measurement). Arterioscler. Thromb. Vasc. Biol. 23:1907-1913.
46. Nishina, P.M., Verstuyft, J., and Paigen, B. 1990. Synthetic low and high fat diets for the study of atherosclerosis in the mouse. J. Lipid Res. 31:859-869.
47. Loike, J.D., et al. 2004. Statin inhibition of Fc receptor-mediated phagocytosis by macrophages is modulated by cell activation and cholesterol. Arterioscler. Thromb. Vasc. Biol. 24:2051-2056.
48. Tamura, Y., et al. 2004. Scavenger receptor expressed by endorhelial cells I (SREC-1) mediates the uptake of acetylated low density lipoproteins by macrophages stimulated with lipopolysaccharide J. Biol. Chem. 279:30938-30944.